Diabetes is diagnosis by hyperglycemia due to absolute or relative deficiency of insulin.
Introduction
Diabetes mellitus is defined as a chronic disorder characterized by elevated plasma glucose concentration resulting from insufficient amount of insulin and insulin resistance, or both along with disturbance in carbohydrate, fat and protein metabolism finally result a hyperglycemia. Diabetes mellitus is a global health problem and several year has becomes a major health problems worldwide. The number of diabetic people is expected to rise to 366 million in 2030 [1] [2] [3] . The numerous synthetic drugs are available for the management of diabetes, and physician usually prescribed them [4] [5] [6] [7] . The use of synthetic drugs often found to be associated with side effects. Hence people are more health conscious and approaching for alternative medicines. The Ayurvedic l formulations are safe to use due to their minimum side effects. Ayurvedic medicine has curative properties due to the presence of many types of complex chemical substance of different composition [8] [9] [10] .
Diabetes mellitus for one therapeutic approach to decrease post-prandial hypoglycemia is to delay the digestion. The α-amylase and α-Glucosidase enzyme hydrolyzed complex polysaccharide to convert in oligosaccharide and disaccharide which are then hydrolyzed by α-Glucosidase enzyme to monosaccharide which are absorbed though the small intestinal in to hepatic portal vein. In vitro models are fairly based on a specific process, where in activity of an enzyme on a metabolic reaction or binding to a receptor. In vitro study is of considerable value in identifying the mechanism of action of a test material and more economical. In vitro assay is an ideal way of obtaining activity for crude extracts and later can be tested in vivo to confirm their effects 11, 12 .
The Meshashringi, Ayurvedic medicine was selected for the present study. Meshashringi is listed in the Indian Pharmaceutical Codex and in Indian popular systems of traditional medicine, such as Sidha, Unani and Ayurveda and many type pharmacological actions. Consequently, it restrains the development of various diseases like ageing, carcinogenesis, obesity and diabetes 13, 14 . Hence we planned to investigate the antidiabetic activity of Meshashringi formulation by in vitro enzyme inhibitory activity.
Materials and Methods

Material
The 
Enzyme inhibitory activities by α-amylase
Enzyme inhibitory activities by α-glucosidase
The α-glucosidase inhibitory activity was determined by min at 37º C, the reaction was terminated by the addition of 2.0 ml of 100 mM sodium carbonate. The liberated p-nitrophenol was determined at 400 nm using spectrophotometer 16 . The % inhibition rates were calculated using the formula,
Enzyme inhibitory activities by Dipeptidyl peptidase IV (DPP-IV)
DPP-IV-inhibitory activity (IC 50 ) was determined using a 
Statistical analysis
The values of results were expressed as mean value ± S.E.M.
the variation in a set of data has been estimated by performing was analysis of variance (ANOVA). Individual comparison of group means values were done by using Graph pad prism 7.01.
Results
Inhibitory activity of Meshashringi on α-amylase enzyme
The finding of inhibitory activity of Meshashringi is represented in the table 1. The IC 50 value of Meshashringi was 106.0 μg/ml for on α-amylase enzyme (Fig 1) . The standard drug Acarbose exhibited 50% inhibition on α-amylase enzyme at 37.80 μg/ml (Fig 2) . The Meshashringi revealed dose dependent inhibitory property for α-amylase enzyme. Values are mean ± SEM of three determinations Values are mean ± SEM of three determinations 
Inhibitory activity of Meshashringi on α-glucosidase enzyme
Meshashringi
The standard drug Acarbose exhibited 50% inhibition on α-glucosidase enzyme at 65.06 μg/ml (Fig 4) . The findings indicate that The Meshashringi produces dose dependent inhibitory property for α-glucosidase enzyme. In addition, the Meshashringi produces lower inhibitory activity for α-glucosidase enzyme compared to α-amylase enzyme. Table 3 exhibited the results of inhibitory activity of
Figure 4: Percentage inhibition of α-glucosidae enzyme by Acarbose
Inhibitory activity of Meshashringi on DPP-IV enzyme
Meshashringi for DPP-IV enzyme. The Meshashringi revealed 50% inhibitory activity for DPP-IV enzyme at 160.67 μg/ml ( Fig   5) . The standard drug Acarbose displayed 50% inhibition on DPP-IV enzyme at 48.22 μg/ml (Fig 6) . The findings indicate that Meshashringi revealed dose dependent inhibitory property for DPP-IV enzyme. Consequently, the Meshashringi produces lower inhibitory activity for DPP-IV enzyme compared to α-glucosidase enzyme and α-amylase enzyme. Values are mean ± SEM of three determinations 
Conclusion
The present study demonstrated that the Meshashringi formulation produces α-amylase, α-glucosidase, and DPP-IV inhibitory activity. It is predicted that Meshashringi suppress the glycemic response in diabetic conditions. The antidiabetic activity of Meshashringi formulation can also be attributed to the intestinal α-amylase, α-glucosidase and DPP-IV inhibitory activity. Further in vivo antidiabetic and cell line study are require to confirm the exact mechanism of Meshashringi.
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